Arthritis and joint care in older dogs: evidence-based management

Osteoarthritis (OA) — degenerative joint disease — is one of the most common chronic conditions in dogs. Estimates vary, but studies suggest it affects approximately 20% of dogs over one year of age and the majority of dogs over seven. It is progressive and incurable, but current management strategies can significantly reduce pain, slow progression and preserve quality of life for years. This is a condition where early diagnosis and a multimodal approach make a real difference.

OA involves the gradual breakdown of articular cartilage, changes to the underlying bone, joint capsule thickening, and chronic low-grade inflammation. Any joint can be affected; the hips, elbows, stifles (knees) and spine are most common in dogs. Certain breeds carry higher inherited risk — Labrador Retrievers, German Shepherds, Golden Retrievers and large and giant breeds generally — but OA can affect any dog, and excess body weight is the single most modifiable risk factor.

Recognising arthritis: the signs at home

Because dogs do not complain verbally and because OA develops gradually, owners often attribute early signs to "getting old." The key clinical indicators, as outlined in IVAPM and WSAVA pain guidelines, include:

• Stiffness after rest, particularly first thing in the morning, that warms off with movement
• Reluctance to jump, climb stairs or get into the car
• Lameness or a subtle change in gait — shifting weight, shortening stride
• Reduced range of motion in a joint (often noticed during grooming or petting)
• Muscle loss (atrophy) over an affected limb due to reduced use
• Licking or chewing at a joint
• Behavioural changes: irritability, reduced interaction, reluctance to be touched
• Changes in sleep and rest patterns

Diagnosis

Diagnosis is based on clinical signs, physical examination (pain response, crepitus and reduced range of motion on joint manipulation, muscle atrophy), and confirmed with radiographs. Radiographic signs include joint space narrowing, osteophyte (bone spur) formation, and subchondral bone sclerosis. It is worth noting that radiographic severity and clinical pain do not always correlate — some dogs with severe X-ray changes show mild symptoms, and vice versa.

Weight management: the highest-impact intervention

Body weight reduction is consistently the most effective single intervention for reducing pain and improving mobility in overweight arthritic dogs. A landmark study found that reducing body weight by 6–8% in overweight dogs with OA significantly improved lameness scores. Every kilogram of excess weight imposes disproportionate loading on joints. If your arthritic dog is above ideal body condition, achieving and maintaining a healthy weight is the priority.

Evidence-based management options

The WSAVA and IVAPM advocate a multimodal approach to OA management — combining pharmacological and non-pharmacological strategies. Single-drug approaches are rarely as effective as a combination.

• NSAIDs (non-steroidal anti-inflammatory drugs): the pharmacological mainstay for OA pain; licensed veterinary NSAIDs (meloxicam, carprofen, grapiprant, etc.) reduce pain and inflammation effectively; require baseline bloodwork and regular monitoring for kidney and liver health
• Gabapentin: commonly added for neuropathic pain components; evidence in dogs is growing
• Polysulphated glycosaminoglycans (PSGAGs, e.g. Cartrophen/Adequan): injectable disease-modifying agents with reasonable evidence for improving joint fluid quality and reducing cartilage degradation
• Omega-3 fatty acids (EPA/DHA from fish oil): anti-inflammatory; multiple studies show benefit in arthritic dogs at appropriate doses (ask your vet for dosing — the amount matters)
• Physiotherapy and hydrotherapy: evidence supports both for maintaining muscle mass, range of motion and function; hydrotherapy (underwater treadmill) is particularly valuable as it offloads joints
• Acupuncture: emerging evidence in veterinary medicine; some dogs respond well as an adjunct
• Anti-nerve growth factor (anti-NGF) therapy: a newer class; bedinvetmab (Librela) is the first licensed anti-NGF monoclonal antibody for OA pain in dogs; given monthly by injection
• Surgical options: for specific joints or underlying causes (e.g. femoral head and neck excision, total hip replacement, tibial plateau levelling osteotomy for cruciate disease) — discuss with a specialist

Environmental modifications

• Orthopaedic foam or memory-foam bed: reduces joint loading during rest
• Non-slip mats on hard floors: prevents painful slipping and fall-related injury
• Ramps to furniture, the car and beds: reduces impact on joints versus jumping
• Raised food and water bowls: reduces neck and spine strain in larger dogs
• Warmth: a warm sleeping environment reduces stiffness; avoid cold, damp floors
• Gentle, consistent exercise: short, frequent walks rather than infrequent long ones; avoid hard stops and starts